Organisation paid for research Program year 2024 Source: CMS Open Payments

Baptist Cardiology Inc

Neither a doctor nor a teaching hospital

Research payments

$192,980

48 payments

Through program year 2024, Baptist Cardiology Inc is reported as receiving $192,980 in research payments, across 48 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $4,810 1
2023 Research $11,076 4
2022 Research $11,075 6
2021 Research $12,701 5
2020 Research $33,299 7
2019 Research $120,020 25

Breakdown

Who paid Research payments · program years 2019–2024
  1. Abbott Laboratories $179,714 37 payments
  2. Boston Scientific Corporation $4,695 9 payments
  3. Amarin Pharma Inc. $4,498 1 payment
  4. AstraZeneca Pharmaceuticals LP $4,073 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $78,579 8 payments
  2. A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions. $28,175 6 payments
  3. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $24,524 5 payments
  4. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $23,776 11 payments
  5. AMPLATZER Amulet LAA Occluder Trial (Amulet IDE) $15,886 5 payments
  6. ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) $8,775 2 payments
  7. LSS of 4 Site $4,695 9 payments
  8. A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio $4,498 1 payment
  9. Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes $4,073 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record